TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00741390

Intervention type: DEVICE
Group type: OTHER
Intervention: BD/33G
Description: BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)

Intervention type: DEVICE
Group type: OTHER
Intervention: BD/33G
Description: BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)

Intervention type: DEVICE
Group type: OTHER
Intervention: BD/33G
Description: BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)

Intervention type: DEVICE
Group type: OTHER
Intervention: BD/33G
Description: BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)

Intervention type: DEVICE
Group type: OTHER
Intervention: OTM / 33G
Description: OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)

Intervention type: DEVICE
Group type: OTHER
Intervention: OTM / 33G
Description: OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
Study: NCT04230317

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest CT
Description: Low dose CT taken with three different protocols
Study: NCT00741390

Intervention type: DEVICE
Group type: OTHER
Intervention: OTM / 33G
Description: OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)

Intervention type: DEVICE
Group type: OTHER
Intervention: OTM / 33G
Description: OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
Study: NCT04230317

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Chest CT
Description: Low dose CT taken with three different protocols
Study: NCT03232996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease
Description: All the participants will take part in an 8 week (twice per week) computer game based exercise program for dual task balance and dual task walk training. Participants will be standing in front of LED monitor. They will be asked to wear a head band which will be instrumented with motion sense mouse. Thus, hands-free head rotations will be used to interact with the computer games selected for the DT rehabilitation program. Participants will play few interactive computer games during - Normal standing (fixed surface), Standing on a compliant sponge pad and then while walking on a treadmill.
Study: NCT01454596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL
Description: Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL
Description: Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
Study: NCT00741390

Intervention type: DEVICE
Group type: OTHER
Intervention: OTU/28G
Description: OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)

Intervention type: DEVICE
Group type: OTHER
Intervention: ACC/28G
Description: Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)

Intervention type: DEVICE
Group type: OTHER
Intervention: OTM/28G
Description: OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
Study: NCT01454596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
Study: NCT00741390

Intervention type: DEVICE
Group type: OTHER
Intervention: OTM/28G
Description: OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
Study: NCT00620282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Stepwise dose increase, s.c. (under the skin) injection, once daily
Study: NCT02412228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Cycle 1:~Ixazomib: 4mg/day 1, 8, 15~Cycles 2-6:~Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18,~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cycle 1:~Cyclophosphamide: 50 mg/day continuous daily~Cycles 2-6:~Cyclophosphamide: 50 mg/day continuous daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycle 1:~Dexamethasone: 20 mg/day 1, 8, 15~Cycles 2-6:~Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18
Study: NCT02703298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-818 capsules
Study: NCT03314701

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic Intermittent Positive Airway Pressure (BIPAP)
Description: Following endotracheal intubation BIPAP mode will be started with:~* Inspiratory positive airway pressure \[IPAP\] at 20 cmH2O~* Expiratory positive airway pressure \[EPAP\] at 5 cmH2O~* PRESSURE SUPPORT is difference between these two pressures \[IPAP\]- \[EPAP\]~* Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airway Pressure Release Ventilation (APRV)
Description: * high airway pressure (Phigh) will be set at 20 cmH2O~* low airway pressure ( Plow) will be set at 5 cmH2O~* the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~* T high at 4.5-6 seconds~* T low at 0.5 to 0.8 second
Study: NCT02838758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: A minimally invasive cryoablation device. It delivers focused nitrous oxide to the target tissue via a 22-gauge needle to create an approximately 9.4mm by 5.4mm spherical freezing zone of temperature between -20 to -100° C.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Roughly 3cc of lidocaine will be injected near the intermetatarsal neuroma under ultrasound visualization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Roughly 3cc of saline will be injected near the intermetatarsal neuroma under ultrasound visualization.
Study: NCT00488488

Intervention type: DRUG
Intervention: tigecycline
Description: The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study: NCT04608565

Intervention type: DEVICE
Group type: OTHER
Intervention: Remote biomonitoring sensor device
Description: Same as described in arm descriptions. Safety was ensured by getting radiant warmer and multichannel probe examined and services by the biomedical engineering department; calibration certificates were obtained and these were used routinely in care of other neonates. An adverse event reporting and resolution protocol for the wearable sensor devices to capture number and severity of adverse events; individual clinical management and feedback for changes into device design. Adverse events recorded were: dermatitis, infection, thermal injury, radiation injury, device leak/burst and others.
Study: NCT00993408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACT-293987 (NS-304)
Study: NCT00490269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Study: NCT00376129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: 15 mg i.m. once weekly for 12 weeks
Study: NCT00867230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTS
Description: Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
Study: NCT02239159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TES(transcutaneous electric stimulation)
Description: Stimulation will be given through electrodes attached to the skin

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: TES(transcutaneous electric stimulation)
Description: Stimulation will be given through electrodes attached to the skin
Study: NCT04392817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arabic Articulatory Error Remediation software program
Description: A speech therapy computerized intervention
Study: NCT01078441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT03523884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program plus Education
Description: Rotator cuff exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
Study: NCT00620282

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets, 1 - 4 mg daily
Study: NCT02666859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: During this intervention, the subjects will be immersed in a virtual reality system called the Computer Assisted Rehabilitation Environment (CAREN) system to complete the tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: During this intervention, the subjects will be immersed in a virtual reality system called the Computer Assisted Rehabilitation Environment (CAREN) system to complete the tasks.
Study: NCT03523884

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program (EP).
Description: An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program (EP).
Description: An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
Study: NCT02868554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcceleDent Aura
Description: Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated Invisalign therapy
Description: Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated Invisalign therapy
Description: Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
Study: NCT02864693

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinnex
Description: The Kinnex is a microprocessor controlled hydraulic ankle foot device (Freedom Innovations, Irvine, CA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacifica LP
Description: The Pacifica LP is a carbon-fiber ankle foot device (Freedom Innovations, Irvine, CA)
Study: NCT00876577

Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
Study: NCT00216671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early initiation of treatment with Risperdal Consta
Description: 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine initiation of treatment with Risperdal Consta
Description: 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
Study: NCT04410185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Meditation sessions will take place over 12 weekly sessions of 1.5 hours
Study: NCT00133406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 0.8gm/kg, ie up to a total daily dose of 16.2gm/day,with juice daily for 10 days
Study: NCT04038541

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)
Description: Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)
Description: Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotics (Visbiome®)
Description: Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotics (Visbiome®)
Description: Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)
Study: NCT03579706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Anxiety Sensitivity Treatment
Description: The Cognitive Anxiety Sensitivity Treatment is a computerized treatment that is a combination of psychoeducation plus interoceptive exposure for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Health Education Training
Description: The Physical Health Education Training is a computerized active placebo matched in time and structure to CAST that includes information about general health and wellness (e.g. diet, exercise etc.).
Study: NCT03390465

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Description: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Description: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Description: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Description: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Description: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Description: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Study: NCT00133406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
Study: NCT03997370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Given IV
Study: NCT02103738

Intervention type: OTHER
Intervention: 0.5 mg Ranibizumab intravitreal injections
Description: All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.

Intervention type: OTHER
Intervention: 0.5 mg Ranibizumab intravitreal injections
Description: All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
Study: NCT00133406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: 100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
Study: NCT04611256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: Two intravenous infusion of 1\*10E6 adipose tissue derived-MSCs /kg body weight reach

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
Study: NCT01627275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Naive T Cell Depleted Donor Lymphocyte Infusion
Description: A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
Study: NCT00275002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Description: Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m\^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m\^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
Study: NCT01328730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firebird 2 SES
Description: The FIREBIRD2™ Rapamycin-Eluting CoCr Coronary Stent is the second generation DES of MicroPort, which based on the new cobalt chromium alloy stent platform. It uses polyolefin polymer, which makes the coating property very remarkable.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher SES
Description: The Cypher SES is based on the 316L platform with Controlled-release, nonresorbable, elastomeric polymer coating.
Study: NCT04826510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perospirone hydrochloride tablets
Description: The dosage of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium carbonate + perospirone hydrochloride
Description: The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate Pill
Description: Lithium carbonate treatment, stable blood lithium concentration 0.5-1.2 mmol / L, course of 8 weeks.
Study: NCT03319056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air purifier
Description: active- or sham-mode air purifier used in 6 classrooms in a school with a crossover design

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Air purifier
Description: active- or sham-mode air purifier used in 6 classrooms in a school with a crossover design